Nodality, Inc. Enters Into A Strategic Collaboration With Johnson & Johnson Innovation In Autoimmune Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc. announced today a strategic collaboration facilitated by the Johnson & Johnson Innovation Center in California under an agreement with Janssen Biotech, Inc. (“Janssen”) to apply Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to immunology R&D programs. The goal of the collaboration is to improve the development and probability of success of compounds for the treatment of rheumatoid arthritis and inflammatory bowel disease by further understanding the biologic function and activity at the single cell level. The agreement also provides an option to develop companion diagnostics that may arise from the collaboration.

Help employers find you! Check out all the jobs and post your resume.